Perpetual Ltd Sells 19,416 Shares of AstraZeneca PLC (NASDAQ:AZN)

Perpetual Ltd cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 44.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,274 shares of the company’s stock after selling 19,416 shares during the period. Perpetual Ltd’s holdings in AstraZeneca were worth $1,590,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Martin Investment Management LLC grew its holdings in shares of AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Nordea Investment Management AB bought a new position in AstraZeneca in the 4th quarter valued at about $754,000. Integrated Advisors Network LLC increased its holdings in AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the period. Creative Planning raised its position in shares of AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after buying an additional 16,692 shares in the last quarter. Finally, Oak Ridge Investments LLC boosted its position in shares of AstraZeneca by 5.4% during the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company’s stock worth $9,433,000 after acquiring an additional 7,341 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 2.0 %

NASDAQ AZN opened at $67.96 on Wednesday. The company has a market cap of $210.75 billion, a price-to-earnings ratio of 32.52, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The business’s fifty day moving average is $66.14 and its 200 day moving average is $74.39.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 earnings per share. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.12 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.